UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Cancer nursing, ISSN 0162-220X, 03/2020, Volume 43, Issue 2, pp. 93 - 104
Nausea questionnaire | Methodology | Cancer care | Nursing theory | Patient-reported outcomes | Symptom documentation | Oncology care | Emesis | Quality of life | Oncology | Nursing | Life Sciences & Biomedicine | Science & Technology | Index Medicus | radiation-induced nausea | participation | chemotherapy-induced nausea | documentation | impact | cancer survivors | management | functional assessment | quality-of-life | Cancer and Oncology | Symptom | prevention | Cancer och onkologi
Journal Article
Supportive care in cancer, ISSN 0941-4355, 5/2017, Volume 25, Issue 5, pp. 1661 - 1671
Chemotherapy-induced nausea and vomiting (CINV) | Pain Medicine | Nursing | Rehabilitation Medicine | Medicine & Public Health | Nursing Research | NK 1 receptor antagonist | Chemotherapy-induced nausea (CIN) | Oncology | Antiemetic guidelines | receptor antagonist | Health Care Sciences & Services | Rehabilitation | Life Sciences & Biomedicine | Science & Technology | Vomiting - chemically induced | Nausea - chemically induced | Antineoplastic Agents - adverse effects | Antiemetics - therapeutic use | Humans | Neurokinin-1 Receptor Antagonists - therapeutic use | Quality of Life - psychology | Prevention | Medical colleges | Chemotherapy | Dexamethasone | Nausea | Patient compliance | Cancer | Side effects | Antagonist drugs | Clinical outcomes | Meta-analysis | Index Medicus | Review | NK1 receptor antagonist
Journal Article
Cancer, ISSN 0008-543X, 12/2003, Volume 98, Issue 11, pp. 2473 - 2482
Dolasetron | 5-HT | receptor antagonist | Antiemetic | Chemotherapy-induced nausea and vomiting | Palonosetron | Life Sciences & Biomedicine | Oncology | Science & Technology | Toxicity: digestive system | Biological and medical sciences | Medical sciences | Drug toxicity and drugs side effects treatment | Pharmacology. Drug treatments | Quinolizines - therapeutic use | Isoquinolines - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Isoquinolines - pharmacology | Quinuclidines - therapeutic use | Antiemetics - therapeutic use | Adult | Antiemetics - adverse effects | Female | Indoles - pharmacology | Quinolizines - adverse effects | Vomiting - prevention & control | Quinuclidines - adverse effects | Severity of Illness Index | Double-Blind Method | Quinuclidines - pharmacology | Treatment Outcome | Quinolizines - pharmacology | Neoplasms - drug therapy | Vomiting - chemically induced | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Isoquinolines - therapeutic use | Indoles - therapeutic use | Aged | Infusions, Intravenous | Antiemetics - pharmacology | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 08/2016, Volume 122, Issue 15, pp. 2418 - 2425
moderately emetogenic chemotherapy | chemotherapy‐induced nausea and vomiting | carboplatin | neurokinin‐1 receptor antagonist | rolapitant | Carboplatin | Moderately emetogenic chemotherapy | Rolapitant | Neurokinin-1 receptor antagonist | Chemotherapy-induced nausea and vomiting | Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Spiro Compounds - therapeutic use | Spiro Compounds - adverse effects | Carboplatin - adverse effects | Neoplasms - complications | Aged, 80 and over | Adult | Female | Nausea - drug therapy | Vomiting - prevention & control | Neurokinin-1 Receptor Antagonists - adverse effects | Chemoprevention | Neurokinin-1 Receptor Antagonists - therapeutic use | Risk Factors | Carboplatin - administration & dosage | Neoplasms - mortality | Treatment Outcome | Vomiting - drug therapy | Neoplasms - drug therapy | Nausea - prevention & control | Nausea - etiology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vomiting - etiology | Aged | Complications and side effects | Care and treatment | Chemotherapy | Nausea | Dosage and administration | Cancer | Index Medicus | Abridged Index Medicus | Original
Journal Article
Supportive care in cancer, ISSN 0941-4355, 12/2012, Volume 20, Issue 12, pp. 3141 - 3148
Pain Medicine | Rehabilitation Medicine | Nursing | Medicine & Public Health | Emetogenous chemotherapy | Oncology | Nursing Management/Nursing Research | Chemotherapy-induced nausea and vomiting | Quality of life | Health Care Sciences & Services | Rehabilitation | Life Sciences & Biomedicine | Science & Technology | Lung Neoplasms - drug therapy | Prospective Studies | Nausea - chemically induced | Humans | Middle Aged | Male | Breast Neoplasms - drug therapy | Nausea - psychology | Neoplasms - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Antineoplastic Agents - adverse effects | Antiemetics - therapeutic use | Vomiting - psychology | Quality of Life | Adult | Female | Surveys and Questionnaires | Aged | Vomiting - prevention & control | Chemotherapy | Cancer patients | Nausea | Cancer | Side effects | Vomiting | Index Medicus
Journal Article
Critical reviews in oncology/hematology, ISSN 1040-8428, 08/2020, Volume 152, pp. 103012 - 103012
NK1 inhibitors | Systematic review | Dexamethasone | Corticosteroids | Chemotherapy-induced nausea and vomiting | Meta-analysis | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Prevention | Medical research | Complications and side effects | Chemotherapy | Analysis | Medicine, Experimental | Nausea | Cancer | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 06/2015, Volume 26, Issue 6, pp. 1081 - 1090
olanzapine | guidelines | chemotherapy-induced nausea and vomiting CINV | NEPA | rolapitant | antiemetics | Antiemetics | Olanzapine | Rolapitant | Chemotherapy-induced nausea and vomiting CINV | Guidelines | Life Sciences & Biomedicine | Oncology | Science & Technology | Nausea - chemically induced | Humans | Neurokinin-1 Receptor Antagonists - therapeutic use | Drug Discovery - trends | Spiro Compounds - therapeutic use | Treatment Outcome | Nausea - prevention & control | Vomiting - chemically induced | Animals | Guideline Adherence | Quinuclidines - therapeutic use | Antineoplastic Agents - adverse effects | Antiemetics - therapeutic use | Serotonin Antagonists | Isoquinolines - therapeutic use | Vomiting - prevention & control | Practice Guidelines as Topic | Pyridines - therapeutic use | Index Medicus
Journal Article
Pediatric blood & cancer, ISSN 1545-5009, 05/2016, Volume 63, Issue 5, pp. 887 - 892
antiemetic | chemotherapy‐induced vomiting | supportive care | pediatrics | nausea | vomiting | Pediatrics | Supportive care | Nausea | Chemotherapy-induced vomiting | Vomiting | Antiemetic | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Child, Preschool | Infant | Male | Neoplasms - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Adult | Female | Surveys and Questionnaires | Child | Vomiting - prevention & control | Chemotherapy | Gastrointestinal agents | Analysis | Pharmacists | Drug therapy | Cancer | Children & youth | Index Medicus | chemotherapy-induced vomiting
Journal Article
Supportive care in cancer, ISSN 0941-4355, 5/2016, Volume 24, Issue 5, pp. 2381 - 2392
Pain Medicine | Nursing | Rehabilitation Medicine | Olanzapine | Medicine & Public Health | Prophylaxis | Oncology | Efficacy | Breakthrough emesis | Nursing Management/Nursing Research | Chemotherapy-induced nausea and vomiting | Health Care Sciences & Services | Rehabilitation | Life Sciences & Biomedicine | Science & Technology | Vomiting - chemically induced | Nausea - chemically induced | Antineoplastic Agents - adverse effects | Antiemetics - therapeutic use | Humans | Antiemetics - administration & dosage | Benzodiazepines - administration & dosage | Female | Benzodiazepines - therapeutic use | Induction Chemotherapy - adverse effects | Chemotherapy | Nausea | Gastrointestinal agents | Analysis | Cancer | Side effects | Vomiting | Meta-analysis | Index Medicus
Journal Article
10.
Full Text
Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients
Expert opinion on pharmacotherapy, ISSN 1465-6566, 04/2013, Volume 14, Issue 6, pp. 757 - 766
cancer treatments | anticipatory nausea and vomiting | emesis | chemotherapy | chemotherapy-induced nausea and vomiting | nausea | vomiting | Anticipatory nausea and vomiting | Chemotherapy | Cancer treatments | Vomiting | Nausea | Emesis | Chemotherapy-induced nausea and vomiting | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Nausea - chemically induced | Humans | Antineoplastic Agents - therapeutic use | Nausea - physiopathology | Nausea - prevention & control | Vomiting - chemically induced | Clinical Trials, Phase III as Topic | Animals | Antineoplastic Agents - adverse effects | Antiemetics - therapeutic use | Drug Design | Quality of Life | Vomiting - physiopathology | Vomiting - prevention & control | Clinical Trials, Phase II as Topic | Practice Guidelines as Topic | Index Medicus | chemotherapy-induced | nausea and vomiting
Journal Article